Azithromycin use before and during the COVID- 19 pandemic and the impact of implementing national evidence-based guidelines in Qatar
Open Access
- 10 November 2024
- journal article
- research article
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 30
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Azithromycin Misuse During the COVID-19 Pandemic: A Cross-Sectional Study from JordanInfection and Drug Resistance, 2022
- Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020PLOS ONE, 2022
- Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in QatarJAMA Internal Medicine, 2021
- Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 InfectionJAMA, 2021
- Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysisClinical Microbiology and Infection, 2021
- Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 eraPublic Health, 2020
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19New England Journal of Medicine, 2020
- Volume and Acuity of Emergency Department Visits Prior To and After COVID-19The Journal of Emergency Medicine, 2020
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York StateJAMA, 2020